Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial

BEVERLY, MA–(Marketwired – Aug 7, 2014) – Cellceutix Corporation (OTCQB: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company’s anti-psoriasis drug candidate Prurisol™ for the conversion of Prurisol to abacavir indicated “the areas are within passing Bioequivalency limits.” Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol™ under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.

Upon receipt of the final report Cellceutix will schedule a meeting with the FDA to advance Prurisol into a Phase 2/3 clinical trial as quickly as possible.